Provectus Biopharmaceuticals (PVCT) CEO gets 8% convertible note grant

Rhea-AI Filing Summary

Provectus Biopharmaceuticals CEO Edward Pershing reported acquiring an 8% unsecured convertible promissory note from the company on February 12, 2026. The note has a principal amount of $30,000 and may be converted into Series D-1 Convertible Preferred Stock at $2.862 per share.

The outstanding principal and interest on the note will automatically convert into Series D-1 preferred stock twelve months after the note’s issue date. Each Series D-1 preferred share is convertible into 10 shares of common stock and will automatically convert into common stock on December 31, 2028 unless converted earlier under its terms.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Pershing Edward

Role CEO

Type	Security	Shares	Price	Value
Grant/Award	8% Unsecured Convertible Promissory Note	0	$0.00	--

Holdings After Transaction: 8% Unsecured Convertible Promissory Note — 0 shares (Direct)

Footnotes (1)

1. The Reporting Person may voluntarily elect to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "Note") at any time while the Note is outstanding into shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Preferred Stock") at a price per share equal to $2.862. The outstanding principal and interest of the Note will automatically convert into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the Note. The Note was issued pursuant to the Issuer's 2025 Financing. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Preferred Stock.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pershing Edward

(Last) (First) (Middle)

800 S. GAY STREET,

SUITE 1610

(Street)

KNOXVILLE TN 37929

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
8% Unsecured Convertible Promissory Note	$2.862	02/12/2026		A		$30,000		02/12/2026	02/12/2027	Series D-1 Convertible Preferred Stock(1)(2)	10,483	$0	$1,320,000	D

Explanation of Responses:

1. The Reporting Person may voluntarily elect to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "Note") at any time while the Note is outstanding into shares of Series D-1 Convertible Preferred Stock, par value $0.001 per share ("Series D-1 Preferred Stock") at a price per share equal to $2.862. The outstanding principal and interest of the Note will automatically convert into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the Note. The Note was issued pursuant to the Issuer's 2025 Financing.

2. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Preferred Stock.

	/s/ Edward Pershing	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did PVCT CEO Edward Pershing report?

Edward Pershing reported acquiring an 8% unsecured convertible promissory note from Provectus Biopharmaceuticals. The note has $30,000 principal and can be converted into Series D-1 preferred stock, which in turn is convertible into common shares under preset terms.

What are the key terms of the 8% unsecured convertible note at PVCT?

The note carries an 8% rate and $30,000 principal, and can be converted into Series D-1 Convertible Preferred Stock at $2.862 per share. Principal and interest automatically convert into Series D-1 preferred stock twelve months after the note’s issue date under the financing terms.

How does PVCT’s Series D-1 preferred stock convert into common stock?

Each Series D-1 Convertible Preferred share converts into 10 shares of Provectus common stock. The Series D-1 preferred stock will automatically convert into common stock on December 31, 2028, unless it is converted earlier according to its certificate of designation.

When will the PVCT CEO’s convertible note automatically convert?

The note’s outstanding principal and interest will automatically convert into Series D-1 Convertible Preferred Stock twelve months after the note’s issue date. This automatic conversion uses a fixed conversion price of $2.862 per Series D-1 preferred share, as specified in the financing terms.

What is the conversion price for PVCT’s Series D-1 preferred stock from the note?

The 8% unsecured convertible note converts into Series D-1 Convertible Preferred Stock at $2.862 per share. This fixed price applies both to voluntary conversions by the reporting person and to the automatic conversion twelve months after the note’s issue date.